ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

GLMD Galmed Pharmaceuticals Ltd

0,3916
-0,0009 (-0,23%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Galmed Pharmaceuticals Ltd GLMD NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,0009 -0,23% 0,3916 00:30:10
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,3949 0,367 0,3949 0,3916 0,3925
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
04.4.202423:06PRNUSGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F..
15.3.202414:00PRNUSGalmed Announces Grant of New Patent for the Combination of..
14.2.202420:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12.2.202422:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
22.11.202322:48EDGAR2Form POS AM - Post-Effective amendments for registration..
20.11.202322:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.11.202322:32PRNUSGalmed Announces a delay in the initiation of its Primary..
01.11.202321:15EDGAR2Form POS AM - Post-Effective amendments for registration..
26.9.202314:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26.9.202314:30PRNUSGalmed Announces Allowance of New Patent for Aramchol for..
22.9.202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22.9.202322:05PRNUSGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum..
21.9.202313:30EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20.9.202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.9.202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.8.202322:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.8.202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.8.202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.7.202316:12EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18.7.202315:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.7.202315:23EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
14.7.202315:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.7.202315:30PRNUSGalmed Pharmaceuticals Announces Pricing of $7 Million..
13.7.202323:08EDGAR2Form F-1/A - Registration statement for certain foreign..
12.7.202323:29EDGAR2Form F-1/A - Registration statement for certain foreign..
10.7.202314:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.7.202314:00PRNUSGalmed to employ OnKai's disruptive Artificial Intelligence..
28.6.202314:40EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28.6.202314:37EDGAR2Form F-1/A - Registration statement for certain foreign..
01.6.202314:00PRNUSGalmed Pharmaceuticals Reports First Quarter 2023 Financial..
09.5.202313:00PRNUSGalmed Announces Initiation of a Clinical Development..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock